Official websites use .mil
Secure .mil websites use HTTPS
July 30, 2025
WRAIR-EME conducts vector surveillance in the Hashemite Kingdom of Jordan
From 26 May – 2 June, a research team from the Walter Reed Army Institute of Research-Europe-Middle East conducted vector surveillance at multiple locations across the Hashemite Kingdom of Jordan.
WRAIR-West’s RISE program expands to Space Force Delta 8
In June 2024, Space Force Delta 8 at Peterson & Schriever Space Force Base implemented Reconnecting to Internal Sensations and Experiences, a training tool spearheaded by the Walter Reed Army Institute of Research-West that improves service members’ resilience and psychological readiness.
June 17, 2025
WRAIR-AFRIMS protects force health at Talisman Sabre 2025
The Walter Reed Army Institute of Research – Armed Forces Research Institute of Medical Sciences conducted disease surveillance in support of exercise Talisman Sabre from 5 May to 11 May in Queensland, Australia.
June 13, 2025
WRAIR-West begins recruitment for study of repetitive mild traumatic brain injury
WRAIR-West has launched two behavioral health studies focused on repetitive mild traumatic brain injuries (mTBI) and occupation-related repetitive exposure to tier-1 weapons, marking a significant step toward strengthening resilience and performance in operational settings.
June 3, 2025
WRAIR's wallet card helps military leaders support soldiers’ mental health
In February 2025, leadership at Fort Huachuca reached out to the Walter Reed Army Institute of Research for support to develop a new tool to support service members prior to mental health crises. As a result of this request, WRAIR developed the wallet card: an easy-to-field reference with specific guidance for leaders about how to start difficult conversations with their soldiers and work together to figure out next steps.
May 30, 2025
The Promise of Bi-Specific Antibodies to Mitigate HIV Risk to the Battlefield Blood Supply
The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) has completed enrollment in a Phase 1 human trial in Tanzania to evaluate the safety and antiviral activity of a long-acting bispecific antibody, alone and in combination with another potent monoclonal antibody, to combat HIV.